Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€20.60

€20.60

0.980%
-
0.980%
-
 
01.08.25 / Tradegate WKN: A2P8F1 / Name: Quantum Biopharma Ltd. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Quantum Biopharma Ltd. Stock

Quantum Biopharma Ltd. gained 0.980% compared to yesterday.
For the coming years our community has positive and negative things to say abot the Quantum Biopharma Ltd. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Unique positioning" there were negative voices in the community.

Pros and Cons of Quantum Biopharma Ltd. in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Quantum BioPharma Announces Joint Clinical Study with Massachusetts General Hospital Scientists
Quantum BioPharma Announces Joint Clinical Study with Massachusetts General Hospital Scientists

Quantum Biopharma Announces Joint Clinical Study with Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor

Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets

 

Toronto, Ontario – March 28, 2025 – Quantum